FDA Greenlights Phio Pharmaceuticals' Trial of PH-762 in Skin Cancer

Phio plans to initiate its Phase 1b clinical trial of intratumoral PH-762 in patients with cutaneous squamous cell carcinomas, melanoma and Merkel cell carcinoma in the second half of 2023.

The U.S. Food and Drug Administration (FDA) has cleared Phio Pharmaceuticals’ Investigational New Drug (IND) application to move ahead with a clinical trial of PH-762 for treating skin cancer.

PH-762 is an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells’ ability to kill cancer cells. Phio plans to initiate its Phase 1b clinical trial of intratumoral PH-762 in patients with cutaneous squamous cell carcinomas, melanoma and Merkel cell carcinoma in the second half of 2023.

“The clearance of our IND application for PH-762 represents a significant milestone in Phio’s continued evolution from drug discovery to clinical development,” says Phio’s President and CEO, Robert Bitterman, in a news release.

Dr. Mary Spellman, Acting Chief Medical Officer, Phio, adds, “Cutaneous malignancies may be both locally destructive and systemically devastating and we look forward to investigating this new immuno-oncology approach to treat these carcinomas.”

The initial multi-center, dose-escalating, Phase 1b clinical trial under Phio’s cleared IND is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762. P

Phio will focus its efforts on the U.S. clinical trial and intends to wind down its first-in-human clinical trial for PH-762 in France, which was limited to the treatment of patients with metastatic melanoma.